Neoadjuvant Combination Immunotherapy for Operable Lung Cancer: NEOSTAR Trial Update

In the phase II randomized NEOSTAR trial, single and combined neoadjuvant immune checkpoint inhibitor therapy yielded an improvement in major pathologic response rates in patients with stage I to III non–small cell lung cancer (NSCLC). Boris Sepesi, MD, of The University of Texas MD Anderson Cancer Center, Houston, and colleagues reported an increase in immunologic memory and tumor immune cell infiltration with the combination neoadjuvant therapy of nivolumab plus ipilimumab. The results of the study were published in Nature Medicine.